Safety and efficacy of 4 difference direct oral anticoagulants, dabigatran, rivaroxaban, apixaban and edoxaban in real-world clinical practice: a single center prospective all-comer registry
Not Applicable
- Conditions
- non-valvular atrial fibrillation
- Registration Number
- JPRN-UMIN000033283
- Lead Sponsor
- Department of Cardiology, Osaka Police Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary safety end point was the occurrence of clinically significant bleeding [a composite of major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and any minor bleeding]. The primary efficacy end point was the occurrence of a major adverse cardiovascular event (a composite of death from cardiovascular causes, myocardial infarction, or stroke).
- Secondary Outcome Measures
Name Time Method Secondary endpoints were each individual components of the primary safety and efficacy endpoints.